DRUG

Bright Minds Biosciences Inc. (DRUG) | Rumor.io

Bright Minds Biosciences

DRUG

Attention (50-day avg)0%

Attention rank (50-day avg)#3,832

Bullish sentiment (50-day avg)100%

Price to earnings ratio0.28

Market capitalization506.9M

Earnings per share-2.01

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-12.2M

Social

What share of all stock conversation is about DRUG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% -0.01

Jan 15

$DRUG's price has surged to $90 from a previous share price of 1000.
The stock's low float and previous over-sold conditions may have contributed to its price increase.
Some investors who previously sold $DRUG at low prices are now regretful, calling it a "scam stock".

Generated by AI

Sentiment

Of the messages about DRUG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	90.14% +6.03
Bearish	—	—	0% 0	9.86% -6.03

Bullish· Jan 6

Bright Minds Biosciences' ($DRUG) recent data beat Longboard's ($LBPH) by a significant margin, highlighting the company's superior efficacy.
The stock's 60% increase in 12 hours and potential parabolic run to $300-$400 demonstrate its strong market momentum.
With a 73.1% efficacy rate and 90% REM sleep boost, $DRUG is positioned for a potential buyout arbitrage, with a logical fundamental target of $300 per share.

Bearish· Jan 6

The price of DRUG has increased significantly, with some users mentioning it went from $1 to $70 in 2024.
Shorting DRUG may be challenging, as some users have successfully bought and held the asset, with one user even saying they're "scared of sell the news".
DRUG has been resistant to dips, with some users joking that shorts will get "rekt" if they try to sell.

Generated by AI

Topics

Of the messages about DRUG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	7.71%
Analysts	—	—	—	5.54%
Announcements	—	—	—	83.86%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	2.89%

Announcements· Jan 6

Bright Minds Biosciences reports positive Phase 2 topline data for BMB-101 in drug-resistant absence seizures and developmental epilepsies, with a 73.1% median reduction in absence seizures and a 63.3% median reduction in major motor seizures.
The company meets primary end points in Phase 2 clinical trial, with significant anti-seizure benefit and favorable safety and tolerability, leading to a premarket stock jump of over 50%.
Bright Minds Biosciences announces the launch of a US$100 million public offering, seeking to raise funds to support the development of its pipeline of brain disorder treatments.

Technical Analysis· Aug 26

The technical analysis of $DRUG suggests that it may be forming a descending triangle or falling wedge pattern, with volume slowing down but still above 101,000,000.
The 200-day MA is acting as a support level for $DRUG, with a potential vwap test coming up from a bounce at $3.41.
The RSI of $DRUG continues to fall, heading towards $2.45, with a significant volume of 91,000,000.

Generated by AI

Community

Of the messages about DRUG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	55.56%	48.4%
Newcomers	100%	100%	44.44%	51.6%

Regulars· Jan 6

The company, Bright Minds Biosciences Inc., has reported positive Phase 2 topline data for its experimental drug BMB-101, which showed a 73.1% median reduction in absence seizures.
The drug's efficacy has been recognized, with the company advancing toward registrational trials and planning a US$100 million public offering to support further development.
The stock's price has surged following the announcement of a collaboration with big pharma, which has led to speculation about the potential for further growth if successful phase 2 results are achieved.

Newcomers· Jan 6

The data from Bright Minds Biosciences' Phase 2 study showed a significant reduction in absence seizures and DEE, but the study was small and open-label, which may impact its reliability.
The company's stock is expected to be highly volatile due to the upcoming release of topline results from the Phase 2 study, and investors should be prepared for significant price swings.
Bright Minds Biosciences has announced the launch of a $100 million public offering of common shares, which may impact the company's stock price and investor sentiment.

Generated by AI

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT:Cantor Global Healthcare Conference 2026 DATE:Wednesday, September 9,

25d agoYahoo Finance

What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?

Does Bright Minds Biosciences Inc. (DRUG) have what it takes to be a top stock pick for momentum investors? Let's find out.

1mo agoYahoo Finance

Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 97% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

1mo agoYahoo Finance

H.C. Wainwright reiterates Bright Minds stock rating at buy

1mo agoInvesting.com

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet

1mo agoYahoo Finance

Bright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal Trials (NASDAQ:DRUG)

1mo agoSeeking Alpha

Also Discussed

Investors talking about DRUG also mention

#	Name	Attention
1	GH Research PLCGHRS	0%0
2	Monopar Therapeutics Inc.MNPR	0%0
3	Carmell CorporationCTCX	0%0
4	Cybin Inc.CYBN	0.01%+0
5	Silo Pharma Inc.SILO	0%new
6	GBNH - Greenbrook TMS Inc.	——
7	Definium Therapeutics, Inc.MNMD	0%+0
8	Mainz Biomed N.V.MYNZ	0%new
9	MicroCloud Hologram Inc.HOLO	0%0
10	Yatsen Holding Ltd.YSG	0%0

Bright Minds Biosciences Inc.

Healthcare
Biotechnology

Bright Minds Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapeutics for neurological and psychiatric disorders. Bright Minds Biosciences Inc. works on next-generation compounds targeting serotonin receptor pathways, with programs aimed at conditions such as epilepsy, depression, pain, and other central nervous system disorders. The company’s research emphasizes selective small-molecule drug candidates designed to address severe and life-altering diseases with high unmet medical need. Its current business is centered on drug discovery and development, supported by a pipeline of preclinical and clinical programs in neurology and psychiatry. Bright Minds Biosciences Inc. operates as a research-driven biotech platform focused on advancing novel therapeutics from early development toward potential clinical use.

Website

Location

19 Vestry Street

New York, NY, 10013

United States

Social

What share of all stock conversation is about DRUG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% -0.01

Jan 15

$DRUG's price has surged to $90 from a previous share price of 1000.
The stock's low float and previous over-sold conditions may have contributed to its price increase.
Some investors who previously sold $DRUG at low prices are now regretful, calling it a "scam stock".

Generated by AI

Sentiment

Of the messages about DRUG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	90.14% +6.03
Bearish	—	—	0% 0	9.86% -6.03

Bullish· Jan 6

Bright Minds Biosciences' ($DRUG) recent data beat Longboard's ($LBPH) by a significant margin, highlighting the company's superior efficacy.
The stock's 60% increase in 12 hours and potential parabolic run to $300-$400 demonstrate its strong market momentum.
With a 73.1% efficacy rate and 90% REM sleep boost, $DRUG is positioned for a potential buyout arbitrage, with a logical fundamental target of $300 per share.

Bearish· Jan 6

The price of DRUG has increased significantly, with some users mentioning it went from $1 to $70 in 2024.
Shorting DRUG may be challenging, as some users have successfully bought and held the asset, with one user even saying they're "scared of sell the news".
DRUG has been resistant to dips, with some users joking that shorts will get "rekt" if they try to sell.

Generated by AI

Topics

Of the messages about DRUG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	7.71%
Analysts	—	—	—	5.54%
Announcements	—	—	—	83.86%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	2.89%

Announcements· Jan 6

Bright Minds Biosciences reports positive Phase 2 topline data for BMB-101 in drug-resistant absence seizures and developmental epilepsies, with a 73.1% median reduction in absence seizures and a 63.3% median reduction in major motor seizures.
The company meets primary end points in Phase 2 clinical trial, with significant anti-seizure benefit and favorable safety and tolerability, leading to a premarket stock jump of over 50%.
Bright Minds Biosciences announces the launch of a US$100 million public offering, seeking to raise funds to support the development of its pipeline of brain disorder treatments.

Technical Analysis· Aug 26

The technical analysis of $DRUG suggests that it may be forming a descending triangle or falling wedge pattern, with volume slowing down but still above 101,000,000.
The 200-day MA is acting as a support level for $DRUG, with a potential vwap test coming up from a bounce at $3.41.
The RSI of $DRUG continues to fall, heading towards $2.45, with a significant volume of 91,000,000.

Generated by AI

Community

Of the messages about DRUG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	55.56%	48.4%
Newcomers	100%	100%	44.44%	51.6%

Regulars· Jan 6

The company, Bright Minds Biosciences Inc., has reported positive Phase 2 topline data for its experimental drug BMB-101, which showed a 73.1% median reduction in absence seizures.
The drug's efficacy has been recognized, with the company advancing toward registrational trials and planning a US$100 million public offering to support further development.
The stock's price has surged following the announcement of a collaboration with big pharma, which has led to speculation about the potential for further growth if successful phase 2 results are achieved.

Newcomers· Jan 6

The data from Bright Minds Biosciences' Phase 2 study showed a significant reduction in absence seizures and DEE, but the study was small and open-label, which may impact its reliability.
The company's stock is expected to be highly volatile due to the upcoming release of topline results from the Phase 2 study, and investors should be prepared for significant price swings.
Bright Minds Biosciences has announced the launch of a $100 million public offering of common shares, which may impact the company's stock price and investor sentiment.

Generated by AI

Bright Minds Biosciences

Social

Jan 15

Bullish· Jan 6

Bearish· Jan 6

Announcements· Jan 6

Technical Analysis· Aug 26

Regulars· Jan 6

Newcomers· Jan 6

Bright Minds Biosciences to Present at Upcoming Conferences

What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?

Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

H.C. Wainwright reiterates Bright Minds stock rating at buy

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet

Bright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal Trials (NASDAQ:DRUG)

Also Discussed

Bright Minds Biosciences Inc.

Company Information

Location

Bright Minds Biosciences to Present at Upcoming Conferences

What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?

Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

H.C. Wainwright reiterates Bright Minds stock rating at buy

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet

Bright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal Trials (NASDAQ:DRUG)

Also Discussed

Social

Jan 15

Bullish· Jan 6

Bearish· Jan 6

Announcements· Jan 6

Technical Analysis· Aug 26

Regulars· Jan 6

Newcomers· Jan 6